Metrics to compare | POLB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPOLBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.5x | −1.5x | −0.4x | |
PEG Ratio | −0.46 | −0.05 | 0.00 | |
Price/Book | 5.7x | 1.6x | 2.6x | |
Price / LTM Sales | - | 2.2x | 3.0x | |
Upside (Analyst Target) | 175.4% | 93.0% | 49.7% | |
Fair Value Upside | Unlock | 8.7% | 7.3% | Unlock |
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is based in London, United Kingdom.